PHBI (Pharmagreen Biotech) Long-Term Debt: $0.12 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharmagreen Biotech Long-Term Debt?

Pharmagreen Biotech PHBI Long-Term Debt is $0.12 Mil as of Jun. 2023.

Pharmagreen Biotech's Long-Term Debt for the quarter that ended in Jun. 2023 was $0.12 Mil.

Pharmagreen Biotech's quarterly Long-Term Debt stayed the same from Dec. 2022 ($0.09 Mil) to Mar. 2023 ($0.09 Mil) but then increased from Mar. 2023 ($0.09 Mil) to Jun. 2023 ($0.12 Mil).

Pharmagreen Biotech's annual Long-Term Debt increased from Sep. 2020 ($0.03 Mil) to Sep. 2021 ($0.04 Mil) and increased from Sep. 2021 ($0.04 Mil) to Sep. 2022 ($0.12 Mil).

Pharmagreen Biotech  (OTCPK:PHBI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pharmagreen Biotech Long-Term Debt Related Terms

Pharmagreen Biotech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech Long-Term Debt Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.03 0.04 0.12

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.12 0.09 0.09 0.12
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.12 Mil mean?
Pharmagreen Biotech (PHBI) has a Long-Term Debt of $0.12 Mil as of Jun. 2023.
Is Pharmagreen Biotech's Long-Term Debt too high?
Pharmagreen Biotech's current Long-Term Debt is $0.12 Mil.
How does Pharmagreen Biotech's Long-Term Debt compare to DVLP and CSTF?
Pharmagreen Biotech's Long-Term Debt of $0.12 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Pharmagreen Biotech's current Long-Term Debt is $0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Long-Term Debt of $0.12 Mil. The current Long-Term Debt is $0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Long-Term Debt is $0.12 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.